FDA Approved: LAZCLUZE — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved Janssen's supplemental NDA for Lazertinib (LAZCLUZE), expanding its use in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LAZCLUZE (LAZERTINIB)

Snippet

SUPPL AP for LAZCLUZE (LAZERTINIB)